Jeff Bezos backs tiny biotech with $130 mil investment

The following is a third-party sponsored message.

It should not be considered a recommendation or endorsement by HS Dent Publishing.

Dear Fellow Investor,

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases.

Most people have never heard of them... but those in the know have been taking notice.

Jeff Bezos cut them a check for $130 million.

Fidelity Biosciences for a further $217 million.

They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

And they have a clean balance sheet with over $1 billion in cash to fund their efforts.

Now, investors are lining up to buy shares.

Stock purchases by institutional buyers more than doubled in the last quarter of 2023.

What is it about this stock that has everyone excited?

Find out more here >>>

"The Buck Stops Here,"

Dylan Jovine, CEO & Founder

Behind the Markets